Aptevo Therapeutics Inc. - Common Stock (APVO)
Frequently Asked Questions About Aptevo Therapeutics Inc. - Common Stock (APVO)
How can investors find more information about Aptevo?
Investors looking for more information about Aptevo Therapeutics can visit the company's official website, where they can find investor relations resources, news releases, financial reports, and updates about ongoing clinical trials. The company also hosts earnings calls and investor presentations that provide insights into its operations and business strategy.
How does Aptevo engage with investors?
Aptevo Therapeutics actively engages with its investors through regular updates, investor presentations, and participation in industry conferences. The company seeks to maintain transparent communication about its research progress, business strategy, and financial performance to keep its shareholders informed.
How does Aptevo ensure research and development quality?
Aptevo Therapeutics is committed to high standards of quality in its research and development processes. The company adheres to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) to ensure that its drug candidates are developed and produced with the utmost safety, efficacy, and regulatory compliance.
How does Aptevo manage its funding?
Aptevo Therapeutics actively manages its funding through a combination of equity financing, strategic partnerships, and grants. The company works diligently to secure the necessary capital to support its research and development efforts while also maintaining financial sustainability and growth.
Is Aptevo publicly traded?
Yes, Aptevo Therapeutics Inc. is publicly traded on the NASDAQ under the ticker symbol 'APVO.' The company's shares are available for purchase by investors, reflecting its commitment to transparency and public engagement as it pursues its mission in the biopharmaceutical sector.
What are some of Aptevo's recent achievements?
Aptevo Therapeutics has achieved several milestones in recent years, including advancements in its clinical development programs, successful fundraising efforts, and submitting applications for investigational new drugs (INDs) with the FDA. These accomplishments demonstrate the company's progress in transitioning innovative therapeutics from the lab to the clinic.
What are the future goals of Aptevo Therapeutics?
Aptevo Therapeutics aims to advance its pipeline of innovative therapies into late-stage clinical trials and ultimately bring effective treatments to market. The company is focused on expanding its portfolio, pursuing strategic collaborations, and contributing to the fight against cancer and other serious diseases through groundbreaking therapeutics.
What challenges does Aptevo face?
Like many biotech companies, Aptevo Therapeutics faces challenges related to drug development, including navigating regulatory pathways, securing funding for research and trials, and the competitive landscape of the biopharmaceutical industry. Successfully bringing a new drug to market requires overcoming significant scientific, financial, and operational hurdles.
What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of cancer and other serious diseases. Utilizing its proprietary technology platforms, Aptevo aims to create innovative antibody-based therapies, which includes their ADAPTIR™ platform that enables the development of bispecific T-cell engagers and other drug candidates.
What is Aptevo's approach to patient engagement?
Aptevo Therapeutics places high importance on patient engagement and advocacy. The company seeks to understand patient needs and preferences by collaborating with patient advocacy groups and incorporating their feedback into its clinical development programs. This approach aims to ensure that treatments developed are aligned with patient expectations.
What is the ADAPTIR™ platform?
The ADAPTIR™ platform is Aptevo's proprietary technology for generating bispecific antibodies, which can target two different antigens simultaneously. This innovative approach enhances the body's immune response against cancer cells and can be utilized to develop a range of therapeutics for both oncology and non-oncology indications.
What is the status of Aptevo's pipeline?
As of October 2023, Aptevo has several drug candidates in its pipeline, including APVO436, a bispecific T-cell engager designed for the treatment of hematologic cancers, and other investigational therapies at various stages of preclinical and clinical development. The company is committed to advancing its innovative products through rigorous research and trials.
What kind of partnerships does Aptevo pursue?
Aptevo Therapeutics values strategic partnerships and collaborations within the biotech and pharmaceutical industries. The company seeks alliances with academic institutions, research organizations, and other biotech firms to enhance its capabilities, access new technologies, and accelerate the development of its therapeutic candidates.
What role does clinical trial data play in Aptevo's strategy?
Clinical trial data is critical to Aptevo Therapeutics' strategy as it provides essential information about the safety and efficacy of its drug candidates. The company uses data from these trials to make informed decisions regarding continued development, regulatory submissions, and potential commercialization.
What therapeutic areas does Aptevo focus on?
Aptevo Therapeutics primarily focuses on oncology, specifically the development of novel therapies for the treatment of blood cancers and solid tumors. The company also explores opportunities in other serious diseases, emphasizing therapies that can address significant unmet medical needs.
When was Aptevo Therapeutics Inc. founded?
Aptevo Therapeutics Inc. was founded in 2016 as a spinout from the biotechnology company Emergent BioSolutions. Since its inception, Aptevo has aimed to leverage its advanced platform technologies and deep industry expertise to develop effective treatments for patients with unmet medical needs.
Where is Aptevo Therapeutics Inc. located?
Aptevo Therapeutics Inc. is headquartered in Seattle, Washington. This location offers access to a vibrant biotech community and enables collaboration with other industry leaders and research institutions.
Who are the key members of Aptevo's management team?
Aptevo Therapeutics boasts a team of experienced professionals with diverse backgrounds in biotechnology and pharmaceutical development. Key members include Dr. Marvin Heffron, CEO, and other leaders with significant experience in translating science into successful therapeutic programs and navigating the complex landscape of drug development.
What is the current price of Aptevo Therapeutics Inc. - Common Stock?
The current price of Aptevo Therapeutics Inc. - Common Stock is 1.405
When was Aptevo Therapeutics Inc. - Common Stock last traded?
The last trade of Aptevo Therapeutics Inc. - Common Stock was at 2:54 pm EDT on April 4th, 2025
What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 16.19M
How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
Aptevo Therapeutics Inc. - Common Stock has 11.52M shares outstanding.